202 related articles for article (PubMed ID: 30782921)
1. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.
Parker L; Karanges EA; Bero L
BMJ Open; 2019 Feb; 9(2):e024928. PubMed ID: 30782921
[TBL] [Abstract][Full Text] [Related]
2. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia.
Fabbri A; Grundy Q; Mintzes B; Swandari S; Moynihan R; Walkom E; Bero LA
BMJ Open; 2017 Jun; 7(6):e016701. PubMed ID: 28667226
[TBL] [Abstract][Full Text] [Related]
3. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
Mulinari S; Ozieranski P
BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
[TBL] [Abstract][Full Text] [Related]
4. How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.
Lau E; Fabbri A; Mintzes B
Aust Health Rev; 2019 Aug; 43(4):474-480. PubMed ID: 30021681
[TBL] [Abstract][Full Text] [Related]
5. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
7. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study.
Moriarty F; Larkin J; Fahey T
Health Policy; 2021 Oct; 125(10):1297-1304. PubMed ID: 34429238
[TBL] [Abstract][Full Text] [Related]
8. Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.
Sawano T; Ozaki A; Saito H; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 May; 2(5):e193817. PubMed ID: 31099864
[TBL] [Abstract][Full Text] [Related]
9. Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare.
Moynihan R; Fabbri A; Parker L; Bero L
BMJ Open; 2020 May; 10(5):e034195. PubMed ID: 32393611
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.
Behdarvand B; Karanges EA; Bero L
BMJ Open; 2019 Aug; 9(8):e030253. PubMed ID: 31434780
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study.
Karanges EA; Nangla C; Parker L; Fabbri A; Farquhar C; Bero L
BMJ Open; 2021 Aug; 11(9):e049710. PubMed ID: 34465582
[TBL] [Abstract][Full Text] [Related]
12. Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016.
Stoll M; Hubenschmid L; Koch C; Lieb K
BMJ Open; 2020 Sep; 10(9):e037395. PubMed ID: 32948560
[TBL] [Abstract][Full Text] [Related]
13. Quantifying Industry Spending on Promotional Events Using Open Payments Data.
Grundy Q; Held F; MacIsaac M; Baugh CM; Campbell EG; Bero L
JAMA Health Forum; 2024 Jun; 5(6):e241581. PubMed ID: 38941087
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme.
Robertson J; Walkom E; Moynihan R; Bero L; Henry D
Int J Pharm Pract; 2010 Apr; 18(2):88-92. PubMed ID: 20441117
[TBL] [Abstract][Full Text] [Related]
15. Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation.
Nissanholtz-Gannot R; Yankellevich A
Isr J Health Policy Res; 2017 Sep; 6(1):45. PubMed ID: 28946915
[TBL] [Abstract][Full Text] [Related]
16. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
17. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories.
Moynihan R; Lai A; Jarvis H; Duggan G; Goodrick S; Beller E; Bero L
BMJ Open; 2019 Feb; 9(2):e025864. PubMed ID: 30813119
[TBL] [Abstract][Full Text] [Related]
18. Health Services and Policy Research in Canada: An Editor's Reflections.
Lexchin J
Healthc Policy; 2022 Feb; 17(3):42-48. PubMed ID: 35319443
[TBL] [Abstract][Full Text] [Related]
19. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
